Evidence map›Paper›PMID 42192422›Full record

ArticleJournal of nanobiotechnology2026

An in situ generated CAR-M with IFN-γ and negative dominance Sirpα isoform augments hepatocellular carcinoma immunotherapy.

Xiang Li, Jing Hu, Tian Zhang, Hongceng Li, Quanrong Lai, Tao Wang, Yuxin Liu, Lan Zhang, Yonglong Wei, Shi Wei and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiang Li *Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, China.
Jing Hu *Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Disease, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Tian Zhang *School of Life Sciences, Yunnan Key Laboratory of Cell Metabolism and Diseases, Yunnan University, Kunming, 650500, Yunnan Province, China.
Hongceng Li *Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Disease, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Quanrong LaiGuangzhou Reverse Pharmaceutical Technology Co., LTD, Guangzhou, 510630, China.
Tao WangGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Disease, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Yuxin LiuGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Disease, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Lan ZhangDepartment of Radiation Oncology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, 519 Kunzhou Road, Kunming, 650118, China. zhanglan@kmmu.edu.cn.
Yonglong WeiSchool of Life Sciences, Yunnan Key Laboratory of Cell Metabolism and Diseases, Yunnan University, Kunming, 650500, Yunnan Province, China. weiyl@ynu.edu.cn.
Shi WeiGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Disease, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 511436, China. weishi@gzhmu.edu.cn.
Panpan ZhangScientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, China. zhangpp25@mail.sysu.edu.cn.

Funding

National Natural Science Foundation of China 82273089National Natural Science Foundation of China 82473133
6 · The paper itself

Abstract

BACKGROUND AND

aimsChimeric antigen receptor (CAR) T cells have shown strong efficacy in hematological cancers but limited success in solid tumors. Macrophages, with their natural ability to infiltrate tumors, modulate immunity, and phagocytose cancer cells, offer a promising alternative when engineered with CARs. While studies have demonstrated the feasibility and anti-tumor activity of CAR macrophages (CAR-M), enhancing their persistence and phagocytic capacity remains a key challenge. METHODS AND

resultsBuilding on first-generation CD3ζ-based CAR-M, we developed a novel CAR targeting human GPC3, incorporating IFN-γ and the extracellular domain of SIRPα (SIRPα

conclusionsCollectively, our work presents a novel CAR design that enhances phagocytic function and sustains anti-tumor activity, offering a promising strategy for human solid tumor immunotherapy.

Indexed as

Antigens, DifferentiationCarcinoma, HepatocellularImmunotherapy, AdoptiveInterferon-gammaLiver NeoplasmsMacrophagesReceptors, Chimeric AntigenReceptors, ImmunologicAnimalsCD47 AntigenCell Line, TumorFemaleHumansImmunotherapyMicePhagocytosisAntigens, DifferentiationCD47 AntigenInterferon-gammaReceptors, Chimeric AntigenReceptors, ImmunologicSIRPA protein, human

Identifiers

PMID42192422
PMCPMC13390385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.